Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Assets (2016 - 2025)

Protalix BioTherapeutics has reported Assets over the past 16 years, most recently at $82.3 million for Q4 2025.

  • Quarterly results put Assets at $82.3 million for Q4 2025, up 12.16% from a year ago — trailing twelve months through Dec 2025 was $82.3 million (up 12.16% YoY), and the annual figure for FY2025 was $82.3 million, up 12.16%.
  • Assets for Q4 2025 was $82.3 million at Protalix BioTherapeutics, roughly flat from $82.3 million in the prior quarter.
  • Over the last five years, Assets for PLX hit a ceiling of $108.2 million in Q2 2021 and a floor of $55.8 million in Q4 2022.
  • Median Assets over the past 5 years was $80.4 million (2025), compared with a mean of $78.5 million.
  • Biggest five-year swings in Assets: tumbled 43.96% in 2022 and later surged 54.42% in 2023.
  • Protalix BioTherapeutics' Assets stood at $73.7 million in 2021, then dropped by 24.27% to $55.8 million in 2022, then skyrocketed by 51.35% to $84.4 million in 2023, then dropped by 13.05% to $73.4 million in 2024, then rose by 12.16% to $82.3 million in 2025.
  • The last three reported values for Assets were $82.3 million (Q4 2025), $82.3 million (Q3 2025), and $78.5 million (Q2 2025) per Business Quant data.